Evidence map›Paper›PMID 40507869›Full record

ArticleInternational journal of molecular sciences2025

Circulating FGF21 and Ketone Bodies Modify the Risk of MASLD and Mortality: Insights from the PREVEND Cohort Study.

Mateo Chvatal-Medina, Yakun Li, Wendy A Dam, Margery A Connelly, Han Moshage, Stephan J L Bakker, Robin P F Dullaart, Adrian Post

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mateo Chvatal-MedinaDepartment of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.ORCID 0000-0003-4310-5657
Yakun LiDepartment of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
Wendy A DamDepartment of Internal Medicine, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
Margery A ConnellyLabcorp, 100 Perimeter Park, Morrisville, NC 27560, USA.ORCID 0000-0002-3917-592X
Han MoshageDepartment of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.ORCID 0000-0002-4764-0246
Stephan J L BakkerDepartment of Internal Medicine, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.ORCID 0000-0003-3356-6791
Robin P F DullaartDepartment of Internal Medicine, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.ORCID 0000-0002-3844-5254
Adrian PostDepartment of Internal Medicine, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.ORCID 0000-0001-8645-1627

Funding

Hartstichting 2001-005Nierstichting E.033
6 · The paper itself

Abstract

Fibroblast growth factor 21 (FGF21) and ketone bodies are markers of metabolic dysregulation, independently associated with metabolic-dysfunction-associated steatotic liver disease (MASLD) and mortality. We studied their interaction with MASLD and all-cause mortality in 6025 participants from the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort. Plasma FGF21 (immunoassay) and ketone body concentrations (nuclear magnetic resonance spectroscopy) were measured at baseline. A Fatty Liver Index ≥60 was used as a proxy of MASLD. Logistic regression assessed associations with MASLD, and Cox models evaluated all-cause mortality over a median follow-up of 10.3 years. FGF21 and ketone bodies were not correlated (r = 0.02,

Indexed as

Fatty LiverFibroblast Growth FactorsKetone BodiesAgedBiomarkersCohort StudiesFemaleHumansMaleMiddle AgedRisk FactorsBiomarkersFGF21 protein, humanfibroblast growth factor 21Fibroblast Growth FactorsKetone Bodiesfibroblast growth factor 21 (FGF21)ketone bodiesmetabolic dysfunction-associated steatotic liver disease (MASLD)mortalityPrevention of Renal and Vascular End-stage Disease (PREVEND) cohort study

Identifiers

PMID40507869
PMCPMC12154048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.